Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have received an average rating of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $31.86.

BCAX has been the subject of a number of research reports. Wall Street Zen cut Bicara Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. HC Wainwright cut their price objective on Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating for the company in a report on Friday, May 16th. Wells Fargo & Company upgraded Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price objective for the company in a report on Friday, May 23rd. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Friday, May 23rd. Finally, Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a report on Thursday, March 27th.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $9.44 on Friday. The business has a 50-day simple moving average of $12.62 and a 200 day simple moving average of $14.56. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). Analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently bought and sold shares of BCAX. California State Teachers Retirement System purchased a new stake in Bicara Therapeutics during the 4th quarter valued at about $25,000. CWM LLC bought a new position in Bicara Therapeutics during the 1st quarter valued at approximately $29,000. Spire Wealth Management bought a new position in Bicara Therapeutics during the 4th quarter valued at approximately $31,000. BNP Paribas Financial Markets bought a new position in Bicara Therapeutics during the 4th quarter valued at approximately $32,000. Finally, Legal & General Group Plc bought a new position in Bicara Therapeutics during the 4th quarter valued at approximately $33,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.